Brian O Mahony/X
Apr 26, 2026, 11:55
Brian O Mahony: Pierce Highlights Unique Inhibitor Cases in AAV-ET3 FVIII Gene Therapy Trial
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared a post on X:
”Pierce on Gene Therapy safety WFH Congress 2026 AAV-ET3 FVIII Human Porcine hybrid Gene Therapy trial in US.
Both participamts developed inhibitors.
These are the only inhibitors seen to date in all the haemophilia clinical trials.”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 13:48Can the Immune System Be Reprogrammed to Treat Aplastic Anemia?
-
Sep 28, 2026, 13:20Elif Susan Elcin։ PRP for Skin Rejuvenation – Is It Worth the Hype?
-
Sep 28, 2026, 13:07Alexandru Stieber: Looking Beyond MDS in VEXAS Syndrome
-
Sep 28, 2026, 12:53Shifa Maharani: Research Innovation and Recognition at JSMID 8th
-
Sep 28, 2026, 12:40Najmul Hasan Forhad: Platelets – The Unsung Heroes of Hemostasis
-
Sep 28, 2026, 12:29Turki Alqahtani: From Routine Testing to Specialized Hematology Diagnostics
-
Sep 28, 2026, 11:26Andra Tocarciuc: Immune TTP in 2026 – Moving Toward Plasma Exchange–Free Care
-
Sep 28, 2026, 11:13Nathan Pennell: 3 Questions That Matter for the Next Multiple Myeloma Treatment
-
Sep 28, 2026, 11:00Oren Rom: Connecting Amino Acid and Lipid Metabolism in MASH